General
Preferred name
orlistat
Synonyms
Ro-18-0647 ()
Tetrahydrolipstatin ()
Ro 18-0647 ()
Xenical ()
ORLISTAT96829-58-2 ()
Orlistat (Ro 18-0647) ()
Tetrahydrolipstatin,Ro 18-0647 ()
Alli (previously orlistat gsk) ()
Ro-180647002 ()
Ro-18-0647-002 ()
Lipstatin ()
ALLI ()
Beacita ()
RO-18-0647/002 ()
Orlipastat ()
RO 18-0647/002 ()
NSC-758881 ()
Ro-180647-002 ()
Orlistat-d3 ()
P&D ID
PD002937
CAS
111397-16-1
104872-04-0
96829-58-2
1356930-46-5
Tags
available
covalent binder
drug
Approved by
FDA
First approval
1998
1999
Drug indication
polycystic ovary syndrome
Obesity
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Orlistat is a lipase inhibitor. Lipase enzymes include gastric and pancreatic lipases, diacylglycerol lipase (DAGL) and αβ-hydrolase 12 (ABHD12). It is used as an anti-obesity drug treatment. At least 18 isomeric forms exist in PubChem.
(GtoPdb)
DESCRIPTION
At least 18 isomeric forms exist in PubChem.
PHARMACODYNAMICS
Orlistat is a lipase inhibitor for obesity management that acts by; inhibiting the absorption of dietary fats. At the recommended; therapeutic dose of 120 mg three times a day, orlistat inhibits; dietary fat absorption by approximately 30%. It works by inhibiting pancreatic lipase, an enzyme that breaks down fat in the intestine. Without this enzyme, fat from the diet is excreted; undigested and not absorbed by the body. Because some vitamins are fat soluble, the effect of orlistat is to reduce their body; absorption. Therefore the drug should only be taken in conjuction with fatty meals, and a multivitamin tablet containing these vitamins (D E K and beta-carotene) should be taken once a day, at least 2 hours before or after taking the drug. In the March 15, 2004 issue of Cancer Research, [1] Steven J. Kridel et al. state that orlistat may also inhibit growth of prostate cancer, and in theory may be useful in treating other cancers, by interfering with the metabolism of fats.
DESCRIPTION
Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity[1].?Anti-atherosclerotic?effect[2].
PRICE
29
DESCRIPTION
Orlistat is a reversible inhibitor of gastrointestinal lipases indicated for weight loss and weight maintenance.
(Enamine Bioactive Compounds)
DESCRIPTION
Selective glycogen phosphorylase inhibitor
(Tocris Bioactive Compound Library)
DESCRIPTION
Pancreatic, gastric and carboxylester lipase inhibitor; antiobesity and antihypercholesterolemic activity
(Tocriscreen Total)
DESCRIPTION
Orlistat (Tetrahydrolipstatin) is a lipase inhibitor and a fatty acid synthase (FASN) inhibitor. Orlistat has been shown to promote weight loss.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
3
Organisms
1
Compound Sets
36
AdooQ Bioactive Compound Library
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Concise Guide to Pharmacology 2025/26
CovalentInDB
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine Bioactive Compounds
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
Tocris Bioactive Compound Library
Tocriscreen Total
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
157
Molecular Weight
495.39
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
1
Rotatable Bonds
23
Ring Count
1
Aromatic Ring Count
0
cLogP
6.88
TPSA
81.7
Fraction CSP3
0.9
Chiral centers
4.0
Largest ring
4.0
QED
0.09
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
MOA
pancreatic lipase inhibitor
Inhibitor
Fatty Acid Synthase Inhibitors
Pancreatic Triacylglycerol Lipase Inhibitors
Gastric Triacylglycerol Lipase Inhibitors
lipase inhibitor
Target
Gastric lipase
Pancreatic lipase
Fatty acid synthase
CNR1, DAGLA, DAGLB, FASN, LIPF, PNLIP
Apoptosis related,Fatty Acid Synthase,Lipase
Fatty Acid Synthase (FASN)
FAS
triacylglycerol lipase
Pathway
Apoptosis
Metabolism
Metabolic Enzyme/Protease
Primary Target
Lipases
Member status
virtual
Indication
weight-loss aid
Biosynthetic Origin
Fatty Acid
Therapeutic Indication
Antiobesity
Therapeutic Class
Metabolic Disorders
Antiobesity Agents
Source data

